Cargando…
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND MET...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441156/ https://www.ncbi.nlm.nih.gov/pubmed/34509803 http://dx.doi.org/10.1016/j.esmoop.2021.100258 |
_version_ | 1783752818936512512 |
---|---|
author | Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A. Zaidi, S. Gelderblom, H. Steeghs, N. Husson, O. van der Graaf, W.T.A. |
author_facet | Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A. Zaidi, S. Gelderblom, H. Steeghs, N. Husson, O. van der Graaf, W.T.A. |
author_sort | Younger, E. |
collection | PubMed |
description | INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND METHODS: The prospective HOLISTIC study was conducted in the UK and the Netherlands assessing health-related quality of life in STS patients receiving palliative chemotherapy. Participants completed a questionnaire before starting chemotherapy, including attitudes towards quality of life (QoL) versus length of life (LoL), decisional control preferences, and decisional conflict. Chi-square and Fisher’s exact tests were used to evaluate associations between patient characteristics and preferences. RESULTS: One hundred and thirty-seven patients with advanced STS participated (UK: n = 72, the Netherlands: n = 65). Median age was 62 (27-79) years. Preference for extended LoL (n = 66, 48%) was slightly more common than preference for QoL (n = 56, 41%); 12 patients (9%) valued LoL and QoL equally (missing: n = 3). Younger patients (age <40 years) prioritised LoL, whereas two-thirds of older patients (aged ≥65 years) felt that QoL was equally or more important than LoL (P = 0.020). Decisional conflict was most common in patients who prioritised QoL (P = 0.024). Most patients preferred an active (n = 45, 33%) or collaborative (n = 59, 44%) role in treatment decisions. Gender, performance status, and country were significantly associated with preferred role. Concordance between preferred and actual role in chemotherapy decision was high (n = 104, 76%). CONCLUSIONS: Heterogeneous priorities and preferences among advanced STS patients support personalised decisions about palliative treatment. Considering individual differences during treatment discussions may enhance communication and optimise patient-centred care. |
format | Online Article Text |
id | pubmed-8441156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84411562021-09-21 Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A. Zaidi, S. Gelderblom, H. Steeghs, N. Husson, O. van der Graaf, W.T.A. ESMO Open Original Research INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND METHODS: The prospective HOLISTIC study was conducted in the UK and the Netherlands assessing health-related quality of life in STS patients receiving palliative chemotherapy. Participants completed a questionnaire before starting chemotherapy, including attitudes towards quality of life (QoL) versus length of life (LoL), decisional control preferences, and decisional conflict. Chi-square and Fisher’s exact tests were used to evaluate associations between patient characteristics and preferences. RESULTS: One hundred and thirty-seven patients with advanced STS participated (UK: n = 72, the Netherlands: n = 65). Median age was 62 (27-79) years. Preference for extended LoL (n = 66, 48%) was slightly more common than preference for QoL (n = 56, 41%); 12 patients (9%) valued LoL and QoL equally (missing: n = 3). Younger patients (age <40 years) prioritised LoL, whereas two-thirds of older patients (aged ≥65 years) felt that QoL was equally or more important than LoL (P = 0.020). Decisional conflict was most common in patients who prioritised QoL (P = 0.024). Most patients preferred an active (n = 45, 33%) or collaborative (n = 59, 44%) role in treatment decisions. Gender, performance status, and country were significantly associated with preferred role. Concordance between preferred and actual role in chemotherapy decision was high (n = 104, 76%). CONCLUSIONS: Heterogeneous priorities and preferences among advanced STS patients support personalised decisions about palliative treatment. Considering individual differences during treatment discussions may enhance communication and optimise patient-centred care. Elsevier 2021-09-09 /pmc/articles/PMC8441156/ /pubmed/34509803 http://dx.doi.org/10.1016/j.esmoop.2021.100258 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A. Zaidi, S. Gelderblom, H. Steeghs, N. Husson, O. van der Graaf, W.T.A. Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title | Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title_full | Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title_fullStr | Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title_full_unstemmed | Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title_short | Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study |
title_sort | priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the holistic study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441156/ https://www.ncbi.nlm.nih.gov/pubmed/34509803 http://dx.doi.org/10.1016/j.esmoop.2021.100258 |
work_keys_str_mv | AT youngere prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT jonesrl prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT denhollanderd prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT soomersvlmn prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT desarime prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT bensonc prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT youngrj prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT oostenaw prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT dehaanjj prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT miaha prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT zaidis prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT gelderblomh prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT steeghsn prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT hussono prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy AT vandergraafwta prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy |